Diligent Appoints Ken Surdan as Chief Product Officer
Diligent Corporation, the leader in Enterprise Governance Management, today announced the appointment of Ken Surdan as Chief Product Officer in the company’s New York City office. Surdan will be tasked with advancing Diligent’s mission to drive innovative technology to governance leaders. This recent hire represents Diligent’s commitment in the governance space to fulfill the need for broader solutions that digitize and securely manage the full range of governance responsibilities. Surdan, as Diligent’s latest strategic investment, joins shortly after the company’s announcement of the Governance Cloud, the only comprehensive suite of governance tools built to help the world’s leading organizations.
“Every day, we’re seeing new headlines reflecting the risks of ineffective governance,” said Diligent CEO Brian Stafford. “Our investment in Ken and his capabilities underlines our deep commitment not only to prepare our clients for today’s governance challenges, but also to push our technology to the next level and drive innovation in the governance space.”
Bringing more than 20 years of experience in product strategy, development and technological innovation, Surdan stands as a SaaS industry veteran with a wealth of experience to scale Diligent’s already expansive suite of governance tools. Surdan has held a variety of executive-level roles at high-growth private and public technology companies. He has built outstanding product and technology teams at innovative companies including Endurance International, Constant Contact and National Leisure Group, an online travel company that he helped grow from $80 million to $900 million in revenue. As an accomplished industry leader with a forward-looking approach to product innovation and governance, Surdan will serve as an essential resource toward furthering Diligent’s corporate strategy.
Serving over 12,000 organizations and 400,000 users worldwide with tools that can be accessed centrally through the Governance Cloud, Diligent proudly introduces Surdan’s appointment as a testament to its unrelenting mission of broadening clients’ ability to digitize their governance responsibilities.
“Diligent is a company I have admired for its unmatched commitment to its clients, as well as its unique opportunity to scale and solve important problems that exist in a rapidly evolving governance marketplace,” said Ken Surdan, Diligent Chief Product Officer. “I look forward to joining Brian and the Diligent team to serve a highly influential set of clients, who love the products we offer.”
Diligent is the leading provider of secure corporate governance and collaboration solutions for boards and senior executives. Over 12,000 clients in more than 90 countries and on all seven continents rely on Diligent for secure distribution of board materials to secure messaging, integrated compliance, board evaluation and entity management. Governance Cloud is the only solution that meets the evolving governance needs of leading organizations. Visit www.diligent.com to learn more.
MWWPR for Diligent
Greg Nyhan, +1 646-215-6884
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Mopria Powers IPP Print Solution in Windows 10 Update19.12.2018 08:00 | Pressemelding
The Mopria® Alliance, a global non-profit membership organization providing universal standards and solutions for print and scan, today announced that Microsoft, a member of the Mopria Alliance, has implemented an IPP printing solution based on the Mopria standard, in the latest version of the Windows 10 operating system. Mopria is a set of standards offering simple and seamless printing to millions of certified printers and multi-function printers. Beginning with Windows 10 October 2018 Update, Windows added support for Mopria certified printers. When users install a new printer and Windows Update is not available, Windows will automatically install the Mopria certified printers. This eliminates the need for users to install any additional software or drivers, allowing them to print easily, regardless of the printer’s brand. “Implementing the Mopria standard in the most recent Windows Update enables us to continue to modernize the printing process for our customers,” said David Lemson
Chugai’s Satralizumab Meets Primary Endpoint in Phase III Monotherapy Study in NMOSD19.12.2018 08:00 | Pressemelding
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that a phase III monotherapy study of satralizumab (development code: SA237), SAkuraStar Study (NCT02073279) for the treatment of neuromyelitis optica spectrum disorder (NMOSD), which currently has no approved treatments, has achieved the primary endpoint. The primary endpoint was time to first protocol-defined relapse in the double-blind period. A statistically significant reduction in the risk of relapse was confirmed in patients who received satralizumab, compared to those who received placebo. Furthermore, the safety profile of satralizumab was consistent with that seen in previous studies. Further details will be presented at a future medical meeting. “We are pleased that satralizumab showed benefits also in a monotherapy setting following the previous results as add-on to baseline treatment in patients with NMOSD,” said Dr. Yasushi Ito, Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit. “We wil
Chugai's Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders19.12.2018 08:00 | Pressemelding
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD). “Satralizumab is a recycling antibody created utilizing Chugai’s proprietary antibody engineering technologies. We are delighted by the FDA’s designation for this innovative antibody based on the results of a Chugai-initiated global Phase III study” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “Satralizumab is designed to inhibit signaling of the inflammatory cytokine IL-6, which is known to play a role in the pathogenesis of NMO/NMOSD. We continue our efforts to hopefully bring satralizumab as a new treatment option as soon as possible to people living with this devastating disease
SES Successfully Placed EUR 400 Million Multi-Tranche Schuldschein Loan19.12.2018 07:50 | Pressemelding
SES S.A., the world’s leading satellite operator, has completed the syndication of Schuldschein Loans for a total amount of EUR 400 million, comprising a EUR 150 million 5.5-year floating tranche at Euribor 6 months plus 0.80% and a EUR 250 million 7-year fixed rate tranche with a coupon of 1.71%. SES is rated Baa2/BBB- (both with stable outlook). The Schuldschein loan was upsized from the initially marketed size and was placed with several European and Asian institutions. The proceeds will support SES’ general corporate purposes and the refinancing of existing debt maturities which include a USD 500 million 144A bond with a coupon of 2.5% and a final maturity date of 25 March 2019. Andrew Browne, Chief Financial Officer of SES, commented: “We are pleased to have secured this financing at very attractive terms and expanding our investor base while extending our debt maturity profile, where we now have no further senior debt maturities to be financed until early 2020.” BNP Paribas, ING
Bentall Kennedy and GreenOak Real Estate Announce Merger to Form Bentall GreenOak, Global Real Estate Investment Platform19.12.2018 07:39 | Pressemelding
Bentall Kennedy and GreenOak Real Estate (“GreenOak”) announced today the signing of an agreement to merge the two firms into a leading global real estate investment platform. The combined entity will be named Bentall GreenOak. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005992/en/ GreenOak Co-Founders, John Carrafiell and Sonny Kalsi, existing GreenOak senior management and GreenOak’s strategic partner Tetragon Financial Group Limited will all continue to hold significant ownership stakes in Bentall GreenOak. Bentall Kennedy’s senior management team will also acquire a meaningful ownership position in the combined firm. Bentall GreenOak will be majority-owned by Sun Life Financial (“Sun Life”) and will operate under Sun Life Investment Management, the alternative asset management arm of Sun Life. Sun Life has committed significant co-investment capital to support the growth of Bentall GreenOak and to enhance the fi
Sun Life Financial to Acquire Majority Stake in Bentall GreenOak19.12.2018 07:37 | Pressemelding
Sun Life Financial Inc. (“Sun Life Financial”) (TSX: SLF) (NYSE: SLF) today announced that it intends to merge Bentall Kennedy, its leading North American real estate and property management firm which Sun Life Financial acquired in 2015, with GreenOak Real Estate (“GreenOak”), a global real estate investment firm with approximately $14 billion (US$11 billion) in assets under management and nine offices globally. Sun Life Financial will acquire a majority stake in the combined Bentall Kennedy and GreenOak entity that will be named Bentall GreenOak and be part of Sun Life Investment Management. Senior management of Bentall GreenOak will include executives from both Bentall Kennedy and GreenOak. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005987/en/ “This transaction is right on strategy, broadening our asset management pillar by expanding the capabilities of our alternatives manager, Sun Life Investment Management,”